764 A phase 1, first-in-human (FIH), open-label, dose-finding and expansion study of XmAb808, a B7H3 x CD28 bispecific antibody, in combination with pembrolizumab in patients with advanced solid tumors

Bupathi, M., Wang, J. S., Hu-Lieskovan, S., Piha-Paul, S. A., Chmielowski, B., Garmezy, B., Najjar, Y. G., Stein, M. N., Yao, L., Kanodia, J., Clynes, R., McGovern, P., & Thompson, B. (2023). 764 A phase 1, first-in-human (FIH), open-label, dose-finding and expansion study of XmAb808, a B7H3 x CD28 bispecific antibody, in combination with pembrolizumab in patients with advanced solid tumors. Regular and Young Investigator Award Abstracts. https://doi.org/10.1136/jitc-2023-sitc2023.0764

Authors:

Manojkumar Bupathi

Judy S Wang

Siwen Hu‐Lieskovan

Sarina A. Piha‐Paul

Bartosz Chmielowski

Benjamin Garmezy

Yana G. Najjar

Mark N. Stein

Li Yao

Jitendra Kanodia

Raphael Clynes